SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-008700
Filing Date
2022-05-10
Accepted
2022-05-10 06:49:14
Documents
69
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cere-20220331.htm   iXBRL 10-Q 2774503
2 EX-31.1 cere-ex31_1.htm EX-31.1 18631
3 EX-31.2 cere-ex31_2.htm EX-31.2 18617
4 EX-32.1 cere-ex32_1.htm EX-32.1 10521
5 EX-32.2 cere-ex32_2.htm EX-32.2 10527
6 GRAPHIC img32104023_0.jpg GRAPHIC 100130
  Complete submission text file 0000950170-22-008700.txt   9606029

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cere-20220331_def.xml EX-101.DEF 213716
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cere-20220331_pre.xml EX-101.PRE 340938
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cere-20220331.xsd EX-101.SCH 54730
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cere-20220331_lab.xml EX-101.LAB 440522
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cere-20220331_cal.xml EX-101.CAL 51353
63 EXTRACTED XBRL INSTANCE DOCUMENT cere-20220331_htm.xml XML 1837666
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39311 | Film No.: 22907269
SIC: 2834 Pharmaceutical Preparations